Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic halides
Reexamination Certificate
2006-10-24
2006-10-24
Davis, Brian J. (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic halides
C546S153000
Reexamination Certificate
active
07126025
ABSTRACT:
This invention provides a compound of Formula (I):whereinS1and S2are each independently, hydrogen, alkyl, alkenyl, alkynyl, aralkyl, substituted or unsubstituted aryl, and S1and S2together with the nitrogen to which they are attached form a nitrogen containing heteroaryl and a pharmaceutically acceptable salt thereof; a method of preparing the compound of Formula (I), and use of the compound of Formula (I) in the preparation of 3-cyano quinolines.
REFERENCES:
patent: 4193983 (1980-03-01), Ullman et al.
patent: 4194050 (1980-03-01), Hazama
patent: 4195021 (1980-03-01), Herron et al.
patent: 4478959 (1984-10-01), Bechara et al.
patent: 4565843 (1986-01-01), Dünwald
patent: 4576759 (1986-03-01), Viehe et al.
patent: 4664825 (1987-05-01), Walsh
patent: 6002008 (1999-12-01), Wissner et al.
patent: 6617333 (2003-09-01), Rabindran et al.
patent: 0 448 078 (1991-09-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 03/020266 (2003-03-01), None
patent: WO 2004/066919 (2004-08-01), None
Wissner, Allan; et al; Synthesis and Structure—Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2); J. Med. Chem., 46:49-63, 2003.
Balenovic, K.; Contribution to the Knowledge of Gamma-Aminocrotonic Acid; J. Org. Chem. 19:1589-1593, 1954.
Traxler P., “Tyrosine kinase inhibitors in cancer treatment (Part II)”, Expert Opinion on Therapeutic Patents, Dec. 1998, vol. 8, No. 12, pp. 1599-1625.
Bridges A.J., “Current progress towards the development of tyrosine kinase inhibitors as anticancer agents”, Emerging Drugs, 1998, 3:279-292.
Mattsson et al., “Current Concepts in Restenosis Following Balloon Angioplasty”, Trends Cardiovasc. Med., Sep. 1995, 5:200-204.
Shaw et al., “Pharmacological inhibition of restenosis: learning from experience”, Trends Pharmacol. Sci., Dec. 1995, 16:401-404.
Raines et al., “Multiple growth factors are associated with lesions of atherosclerosis: specificity or redundancy?”, Bioessays, Apr. 1996, 18(4):271-282.
Shawver et al., “Receptor tyrosine kinases as targets for inhibition of angiogenesis”, Drug Discovery Today, Feb. 1997, 2(2): 50-63.
Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease”, Nat Med., Jan. 1995, 1(1):27-31.
Boyce et al., “Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice”, J Clin Invest., Oct. 1992, 90(4):1622-1627.
Marszak I. et al., “Recherches sur les Aminoacides et Leurs Derives. I.-sur la Synthese des Aminoacides a Partir des Amines Tertiaires a Fonction Acetylenique Vrai Amino Acids and Their Derivatives. I. The Synthesis of Amino Acids From Tertiary Amnes Having a True Acetyl”, Bulletin de la Societe Chimique de France, Societe Francaise de Chimie, 1959, pp. 182-185.
European Search Report for European Patent Application No. 05019642.7 (Mar. 30, 2006).
Chew Warren
Considine John Leo
Daigneault Sylvain
Duncan Scott Mason
Iera Silvio
Davis Brian J.
Howson & Howson
Mazzarese Joseph M.
Wyeth
LandOfFree
Synthesis of 4-(amino)-2-butenoyl chlorides and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis of 4-(amino)-2-butenoyl chlorides and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of 4-(amino)-2-butenoyl chlorides and their use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3674196